Abstract
Molecular imaging can be used to evaluate the spatial–time change of the molecular biological phenomenon of the cell–molecule level in living bodies. Molecular imaging technology is expected to be applied in the fields of drug development, clinical diagnosis, and life science research. Specifically, positron emission tomography (PET) is a powerful non-invasive imaging technology for investigating physiological parameters in living animals using compounds labeled with PET radioisotopes as molecular probes. This review summarizes and compares various 18F-conjugation techniques that employ the chemical and enzymatic reactions of different types of tumor-targeting biological molecules such as peptides, proteins, antibodies, and nucleic acids.
Keywords: Chemoenzymatic reaction, Chemical reaction, Positron emission tomography (PET) probe, Biologics, Biopharmaceutics, Fluorine-18 (18F), Peptide, Protein, Oligonucleotide, Antibody, Click chemistry, Tumor targeting.
Current Topics in Medicinal Chemistry
Title:18F-Containing Positron Emission Tomography Probe Conjugation Methodology for Biologics as Specific Binders for Tumors
Volume: 16 Issue: 24
Author(s): Kenji Arimitsu, Hiroyuki Kimura, Yoshinari Arai, Kazuto Mochizuki and Masumi Taki
Affiliation:
Keywords: Chemoenzymatic reaction, Chemical reaction, Positron emission tomography (PET) probe, Biologics, Biopharmaceutics, Fluorine-18 (18F), Peptide, Protein, Oligonucleotide, Antibody, Click chemistry, Tumor targeting.
Abstract: Molecular imaging can be used to evaluate the spatial–time change of the molecular biological phenomenon of the cell–molecule level in living bodies. Molecular imaging technology is expected to be applied in the fields of drug development, clinical diagnosis, and life science research. Specifically, positron emission tomography (PET) is a powerful non-invasive imaging technology for investigating physiological parameters in living animals using compounds labeled with PET radioisotopes as molecular probes. This review summarizes and compares various 18F-conjugation techniques that employ the chemical and enzymatic reactions of different types of tumor-targeting biological molecules such as peptides, proteins, antibodies, and nucleic acids.
Export Options
About this article
Cite this article as:
Arimitsu Kenji, Kimura Hiroyuki, Arai Yoshinari, Mochizuki Kazuto and Taki Masumi, 18F-Containing Positron Emission Tomography Probe Conjugation Methodology for Biologics as Specific Binders for Tumors, Current Topics in Medicinal Chemistry 2016; 16 (24) . https://dx.doi.org/10.2174/1568026616666160413125948
DOI https://dx.doi.org/10.2174/1568026616666160413125948 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not Related to Disease Severity
Current Rheumatology Reviews Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke
Current Medicinal Chemistry The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Nanotoxicity: The Toxicity Research Progress of Metal and Metal- Containing Nanoparticles
Mini-Reviews in Medicinal Chemistry Nanoparticles in Melanoma
Current Medicinal Chemistry Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry p53: Fighting Cancer
Current Cancer Drug Targets